
Michael Duruisseaux/X
Apr 14, 2025, 04:39
Michael Duruisseaux: Phase 3 DeLLphi-304 – Tarlatamab Meets OS Endpoint in SCLC
Michael Duruisseaux, Medical Director of the Joint Research Unit in Thoracic Oncology of the Hospices Civilians of Lyons, shared a post on X:
“Phase 3 DeLLphi-304 is clinical trial evaluating Tarlatamab vs SOC chemo in SCLC who progressed after front-line platinum-based chemo met its primary endpoint of OS. Can’t wait to see the data.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 07:23
Apr 15, 2025, 07:10
Apr 15, 2025, 07:04